Back log

Code No: G-13021/PCI

# FACULTY OF PHARMACY

**M. Pharmacy (Regulatory Affairs) I Semester (PCI) Backlog Examination, December 2024**
**Subject: Documentation and Regulatory Writing**

**Time: 3 Hours** **Max.Marks:75**

**Note:** Answer any 5 questions. All questions carry equal marks.

1. (a) Explain the goals and give the template of Exploratory Product Development Brief (EPDB) documentation. (8)
   (b) Give an account on Batch Manufacturing records and explain its calculations.(7)
2. (a) Describe purpose, scope and the contents of Site Master File (8)
   (b) Explain the rationale and sections of Product Development Report (PDR) (7)

3. (a) Write a note on Electronic Submission gateways (ESG) (5)
   (b) Explain the architecture and Submission of eCTD. (10)

4. Describe the dossier submission procedure involved in SUGAM system. (15)
5. (a) Explain the types of audits in pharmaceutical facility. (8)
   (b) Explain the purpose of Global Harmonization Task Force (GHTF) Study group 4 guiding document. (7)
6. (a) What is the purpose of CAPA? Explain the process of CAPA for Pharmaceutical industry. (8)
   (b) Describe in detail about root cause analysis. (7)

7. (a) What are SUPAC guidelines? Explain post approval changes recommendations provided for components and composition changes. (9)
   (b)Write a note on CBE 0 and CBE 30. (6)

8. Write short notes on
   (a). FDA Warning letters (7.5)
   (b). Pre-approval inspections. (7.5)

******

Code No: G-13020/PCI

# FACULTY OF PHARMACY

**M. Pharmacy (Pharm. Regulatory Affairs) I-Semester (PCI) (Backlog) Examination, December 2024**

**Subject: Good Regulatory Practices**

**Time: 3 Hours** **Max. Marks: 75**

**Note: Answer any five questions.** **(5 x 15 = 75 Marks)**

1. Describe US cGMP guidelines 21CFR Part 210 and 211. (15)

2. (a) Write a note on GLP inspection process. (8)
   (b) Write a note on future of GLP regulations. (7)

3. (a) What are the goals of laboratory Quality Audit. (6)
   (b) Describe WHO cGMP guidelines. (9)

4. (a) Explain 21 CFR Part 11. (9)
   (b) Describe ISO and Quality Council of India (QCI) Standards for GALP. (6)

5. (a) Write a note on USP GDP. (10)
   (b) Write a note on principles of Good Distribution Practices. (5)

6. (a) Write about Total Quality Management concepts. (10)
   (b) Describe Change control. (5)

7. (a) Write a note on types of validation and types of qualification. (6)
   (b) Describe CDSCO guidelines for Good Distribution Practices. (9)

8. (a) Write a note on SOPs of GALP. (8)
   (b) Write a note on ISO 13485. (7)

*********

Backlog

Code No: G-13023/PCI

# FACULTY OF PHARMACY

**M. Pharmacy (Pharmaceutical Regulatory Affairs) I - Semester (PCI) (Backlog) Examination, December 2024**

**Subject: Regulations and Legislation for Drugs & Cosmetics, Medical Devices, Biologicals & Herbal, and Food & Nutraceuticals in India and Intellectual Property Rights**

**Time: 3 Hours** **Max Marks: 75**

**Note : Answer any five questions. All questions carry equal marks.**

1. (a) What are the objectives of CPCSEA (CCSEA). Describe the guidelines in conducting the animal experimentation.
   (b) Write a note on guidelines for human participants. [10+5]

2. Define Intellectual property rights. Explain the types IPR. [15]

3. (a) Write in detail about the organization, functions and responsibilities of CDSCO. [8+7]
   (b) Describe the format of regulatory dossier for clinical trial investigation.

4. Write about [5+5+5]
   (a) Classes of advertisements exempted according to Drugs and magic remedies act.
   (b) Construction of Bonded laboratory.
   (c) Narcotic drugs and Psychotropic substances act.

5. Write an informative note on [9+6]
   (a) Copyright
   (b) Trademarks

6. (a) Write about the BCS classification drugs. [7+8]
   (b) Write the definition and objectives patent act. Write note non patentable concepts.

7. What are Medical devices? Classify and write the regulatory guidelines for filling of medical devices. [15]

8. (a) Describe the objectives and principles of NPPA.
   (b) Write the objectives of DPCO. Explain the fixing of ceiling prices of various formulations. [5+10]

*****

Code No: F-7259/PCI

# FACULTY OF PHARMACY

**M. Pharmacy (Pharma. Regulatory Affairs) I-Semester (PCI) (Main & Backlog) Examination, June 2024**

**Subject: Good Regulatory Practices**

**Time: 3 Hours** **Max. Marks: 75**

**Note: Answer any five questions.** **(5 x 15 = 75 Marks)**

1. (a) Describe GMP principles of Europe Union (directive 91/356/EEC). (8)
   (b) Write a note on WHO cGMP guidelines. (7)

2. (a) Describe USFDA GLP Regulations. (10)
   (b) Explain the types of Audits. (5)

3. (a) Explain the CFR Part 210. (5)
   (b) Describe ISO and Quality Council of India (QCI) Standards for GLP. (10)

4. (a) Describe the general check list of 21 CFR Part 11. (8)
   (b) Describe principles and SOPs of Good Automated Laboratory Practices (GALP). (7)

5. (a) Write about Documentation in Good Distribution Practices. (5)
   (b) Write about WHO GDP. (10)

6. (a) Describe concept of Quality. (5)
   (b) Explain HVAC Validation (Heat Ventilation and Air conditioning). (10)

7. (a) Write the contents of Validation Master Plan. (7)
   (b) Explain about ICH guidelines. (8)

8. (a) Describe GALP requirements and documentation. (8)
   (b) Explain about principles of GDP. (7)

*********

Code No: F-7261/PCI

# FACULTY OF PHARMACY

**M. Pharmacy (Pharma. Regulatory Affairs) I - Semester (PCI) (Main & Backlog) Examination, June 2024**

**Subject: Clinical Research Regulations**

**Time: 3 Hours** **Max. Marks: 75**

**Note: Answer any five questions.** **(5 x 15 = 75 Marks)**

1. (a) Write a note on clinical investigation of Medical Devices. (8)
   (b) Write a note on types of clinical studies. (7)

2. Write in detail about different phases of clinical trials. (15)

3. (a) Describe the responsibilities of Sponsor and investigator in conduct of clinical research. (9)
   (b) Write a note on Composition and role of Ethics committee. (6)

4. (a) Explain clinical research regulations in European Union (EMA). (8)
   (b) Describe FDA Guidance for Industry for Acceptance of Foreign Clinical Studies. (7)

5. (a) Explain the ICH E4 guidelines with regard to dose response information. (9)
   (b) Explain GHTF Group 5 guidance documents. (6)

6. (a) Discuss about 21 CFR Part 312, IND Application. (8)
   (b) Write a note on EU MDD with respect to clinical research. (7)

7. (a) Write a note on CFR 21 Part 50. (9)
   (b) Write a note on role of placebo in clinical trials. (6)

8. (a) Write a note on Informed consent form. (7)
   (b) Write a note ICH E10 Guidelines. (8)

*********

Code No: F-7262/PCI

# FACULTY OF PHARMACY

**M. Pharmacy (Pharmaceutical Regulatory Affairs) I - Semester (PCI) (Main & Backlog) Examination, June 2024**

**Subject: Regulations and Legislation for Drugs & Cosmetics, Medical Devices, Biologicals & Herbal, and Food & Nutraceuticals in India and Intellectual Property Rights**

**Time: 3 Hours** **Max Marks: 75**

**Note : Answer any five questions. All questions carry equal marks.**

1. (a) Describe the objectives and principles of NPPA. [5+10]
   (b) Write the objectives of DPCO. Explain the fixing of ceiling prices of various formulations.

2. Write about [5+5+5]
   (a) Classes of prohibited advertisements according to Drugs and magic remedies act.
   (b) Construction of Bonded laboratory.
   (c) Narcotic drugs and Psychotropic substances act

3. (a) Define the terms Nutraceuticals, medical devices, cosmetics, advertisements and magic remedies.
   (b) Write an informative note on Geographical Indications. [8+7]

4. What are Medical Devices? Describe the regulations and guidelines for approval of Medical devices. [15]

5. Write the importance of stability studies. Describe the stability requirements as per the ICH. [15]

6. Write a note on:
   (a) Regulatory requirements for Bioequivalence studies.
   (b) Trademarks. [8+7]

7. (a) Give the definition and objectives of patent act. Discuss the patentee rights. [8+7]
   (b) Give an informative note on CPCSEA (CCSEA) guidelines on animal experimentation.

8. Define Intellectual Property Rights. Narrate the types of IPRs. [15]

*****

Code No: F-7260/PCI

# FACULTY OF PHARMACY

**M. Pharmacy (Regulatory Affairs) I - Semester (PCI) (Main & Backlog) Examination, June 2024**

**Subject: Documentation and Regulatory Writing**

**Time: 3 Hours** **Max. Marks: 75**

**Note: Answer any five questions. All questions carry equal marks.**

1. Write a detailed note on Product development plan. Explain various sections of Pharmaceutical Product Development Report.

2. (a) Describe the batch manufacturing record and explain the calculations with example. [10]
   (b) Write a note on Certificate of analysis. [5]

3. Explain the architecture, Submission and validation of electronic Common Technical Document (eCTD).

4. (a) Describe the aim, requirement and organization of ASEAN Common Technical Dossier (ACTD). What is the difference between eCTD (ICH CTD) and ACTD? [12]
   (b) Explain Electronic Submission Gateways (ESG). [3]

5. (a) Explain the purpose of Global Harmonization Task Force (GHTF) Study group 4 guiding document. [7]
   (b) Explain in detail about various types of audits in pharmaceutical facilities. [8]

6. (a) What is the purpose of CAPA? Describe the steps involved in CAPA implementation process. [8]
   (b) Explain the benefits and tools of Root cause analysis. [7]

7. (a) Describe general requirements for post approval changes. [10]
   (b) Give an account on Establishment Inspection report (EIR). [5]

8. Write short notes on
   (a) ISO 13485 [7.5]
   (b) FDA inspection process for drug distribution channels [7.5]

*****

Code No: E-12441/PCI

# FACULTY OF PHARMACY

**M. Pharmacy (Pharm. Regulatory Affairs) I-Semester (PCI) (Backlog) Examination, November-2023**

**Subject: Good Regulatory Practices**

**Time: 3 Hours** **Max. Marks: 75**

**Note: Answer any five questions. All questions carry equal marks.**

1. (a) Write a note on Global Harmonization Task Force (GHTF) guidance documents. [8]
   (b) Write a note on WHO cGMP guidelines. [7]

2. (a) Explain the types of Audits and Audit tools. [10]
   (b) What are the goals of laboratory Quality Audit? [5]

3. (a) Explain the CFR Part 210. [5]
   (b) Describe USFDA GLP Regulations. [10]

4. (a) Describe the general check list of 21 CFR Part 11. [8]
   (b) Describe principles and SOPs of GALP. [7]

5. (a) Write about Principles and Documentation in Good Distribution Practices. [8]
   (b) Write a note on USP GDP. [7]

6. (a) Describe Six Sigma concept. [5]
   (b) Explain Quality by Design tool for Quality Management. [10]

7. (a) Write a note on Types of Validation. [7]
   (b) Explain about ICH guidelines. [8]

8. (a) Describe ISO and QCI standards for GALP. [8]
   (b) Explain about HVAC validation. [7]

******

Code No: E-12442/PCI

# FACULTY OF PHARMACY

**M. Pharmacy (Pharm. Regulatory Affairs) I Semester (PCI) (Backlog) Examination, November 2023**

**Subject: Documentation and Regulatory Writing**

**Time: 3 Hours** **Max. Marks: 75**

**Note: Answer any five questions. All questions carry equal marks.**

1. (a) Explain the importance of EPDB for drug substance and drug products. [7]

   (b) Explain the batch formula records in detail. [8]

2. (a) Describe the contents of Site Master File. [10]

   (b) What is product development report (PDR)? Discuss the significance of PDR. [5]

3. (a) Describe the modules of ICH-CTD format with granularity. [10]

   (b) Define and compare paper CTD and electronic CTD. [5]

4. (a) Describe the aim , requirement and organization of ASEAN Common Technical Dossier (ACTD). [9]

   (b) Write a note on Electronic Submission gateways. [6]

5. (a) Discuss the internal and external Audits in detail. [8]

   (b) Explain the purpose of Global Harmonization Task Force (GHTF) study group 4 guiding document. [7]

6. (a) Write a detailed note on Pre-approval Inspections. [7.5]

   (b) Outline FDA inspection process for drug distribution channels. [7.5]

7. (a) Discuss the Post Approval Changes (SUPAC) process for an approved drug product. [10]

   (b) Write a note on Prior approval supplement. [5]

8. Write short notes on

   (a) Importance and steps involved in root cause analysis. [7.5]

   (b) CBE 30. [7.5]

******

Code No: E-12443/PCI

# FACULTY OF PHARMACY

**M. Pharmacy (Pharm. Regulatory Affairs) I Semester (PCI) (Backlog) Examination, November 2023**

**Subject: Clinical Research Regulations**

**Time: 3 Hours** **Max. Marks: 75**

**Note: Answer any five questions. All questions carry equal marks.**

1. (a) Write a note on Phase I and Phase III clinical trials. [6]
   (b) Write a note on Clinical Trial protocol. [9]

2. (a) Describe the Historical perspectives that resulted in ethics to be followed in clinical research. [10]
   (b) Describe the Informed consent process. [5]

3. (a) Write a note on clinical research regulations in Europe Union (EMA) [9]
   (b) Describe guidelines for Medical Devices in India. [6]

4. (a) Explain the ICH E6 guidelines with regard to Good Clinical Practice. [9]
   (b) Describe ICMR ethical guidelines for biomedical research. [6]

5. (a) Write a note on CFR 21 Part 50 with regard to protection of human subjects. [9]
   (b) Explain ISO 14155. [6]

6. Discuss about
   (a) ANDA 505(j) of the FD&C Act. [5]
   (b) Responsibilities of sponsor, CRO and investigator in ethical conduct of clinical research. [10]

7. Write a note on
   (a) Europe union Eudralex volume 3 guidelines. [10]
   (b) ICH E9 with regard to general biostatics principle applied in clinical research. [5]

8. Write a note on
   (a) Randomized clinical trials. [8]
   (b) Instituitonal review board. [7]

******

**Code No: E-12444/PCI**

# FACULTY OF PHARMACY

**M. Pharmacy (Pharmaceutical regulatory Affairs) I Semester (PCI) (Backlog) Examination, November 2023**

**Subject: Regulations and Legislation for Drugs and Cosmetics, Medical Devices, Biologicals and Herbal and Food and Nutraceuticals in India and Intellectual Property Rights**

**Time: 3 Hours** **Max.Marks:75**

**Note: Answer any five questions. All questions carry equal marks.**

1. a) What are Medical Devices? Describe the regulations and guidelines for approval of Medical devices.
   b) Describe the content and format for preparation of clinical trial dossier. [9+6]

2. Describe the objective of DPCO and NPPA. Explain the methods of price fixation of bulk drugs, formulations and new drugs. [15]

3. a) Define the terms Advertisement, Magic remedies, Nutraceuticals, Cosmetics and formulations.
   b) Describe the organization, functions and responsibilities of state pharmacy council. [7+8]

4. a) What is patent? Write about the objectives, rights of patentee.
   b) Define Intellectual Property Rights. Narrate the types of IPRs. [6+9]

5. What are the objectives of?
   a) Pharmacy act; b) Narcotic drugs and Psychotropic substances act;
   c) CPCSEA; d) CDSCO e) Medicinal and Toilet preparation act. [15]

6. a) Explain the constitution and functions of Pharmacy council of India. [7+8]
   b) Give an informative note on Copyrights.

7. a) Differentiate between bonded and non bonded laboratory. Describe the construction of bonded laboratory. [8+7]
   b) Give an informative note on CPCSEA guidelines on animal experimentation.

8 a) Describe the regulatory requirement for conducting BA and BE studies [8+7]
   b) Write an informative note on ICH guidelines for stability studies.

*******